Gilead's $11B Pharmasset Buy Validates Nuc Prodrug Strategy
By Marie Powers
Tuesday, November 22, 2011
Thanksgiving came early for Pharmasset Inc. with the news that Gilead Sciences Inc. will gobble it up in a deal valued at $11 billion.
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.